Foghorn Therapeutics (FHTX) Accumulated Expenses (2020 - 2025)
Historic Accumulated Expenses for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $9.8 million.
- Foghorn Therapeutics' Accumulated Expenses fell 1245.21% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 1245.21%. This contributed to the annual value of $8.5 million for FY2024, which is 633.51% down from last year.
- As of Q3 2025, Foghorn Therapeutics' Accumulated Expenses stood at $9.8 million, which was down 1245.21% from $8.6 million recorded in Q2 2025.
- Foghorn Therapeutics' Accumulated Expenses' 5-year high stood at $11.2 million during Q3 2024, with a 5-year trough of $5.1 million in Q1 2021.
- Its 5-year average for Accumulated Expenses is $8.2 million, with a median of $8.5 million in 2024.
- In the last 5 years, Foghorn Therapeutics' Accumulated Expenses skyrocketed by 5714.29% in 2022 and then crashed by 2905.67% in 2024.
- Over the past 5 years, Foghorn Therapeutics' Accumulated Expenses (Quarter) stood at $9.6 million in 2021, then increased by 15.05% to $11.0 million in 2022, then fell by 17.21% to $9.1 million in 2023, then decreased by 6.34% to $8.5 million in 2024, then rose by 15.13% to $9.8 million in 2025.
- Its Accumulated Expenses was $9.8 million in Q3 2025, compared to $8.6 million in Q2 2025 and $6.5 million in Q1 2025.